Suppr超能文献

袖状胃切除术的 5 年结果。

Five-year results of sleeve gastrectomy.

机构信息

Service de chirurgie viscérale, centre hospitalier de Saint-Denis, 2, rue du Docteur-Delafontaine, 93200 Saint-Denis, France.

出版信息

J Visc Surg. 2013 Nov;150(5):307-12. doi: 10.1016/j.jviscsurg.2013.08.008. Epub 2013 Sep 21.

Abstract

OBJECTIVE

Our purpose was to evaluate the efficacy and safety of sleeve gastrectomy (SG) at 5 years after surgery.

PATIENTS AND METHODS

From June 2005 to January 2007, 65 obese patients underwent SG. The percentage of excess weight loss (%EWL) and excess BMI loss (% EBL), obesity-related co-morbidities, and post-SG complications were evaluated at 2 years after SG based on our database, and at 5 years after SG based on a questionnaire sent to the patients by one of the authors (IB) between May 2011 and February 2012.

RESULTS

A complete data set was obtained for 53 of 65 patients (82%), including 45 patients who had SG as the only surgical treatment, and eight patients who had a second bariatric procedure at a later date because of insufficient weight loss (five gastric bypass (GBP), three SG revision). For these 53 patients, the mean %EWL was 54.4% at 2 years and 53.7% at 5 years, and the mean %EBL was 61% at 2 years and 60% at 5 years. Three patients (5.7%) had post-operative complications (two fistulas (3.8%), one hemorrhage (1.9%)). Three trocar-site hernias (5.7%) were observed between 10 months and 34 months post-SG. Sub-group analysis of the 45 patients who underwent SG alone showed a mean %EWL of 57.1% at 2 years and 50.7% at 5 years; the mean %EBL was 64% at 2 years and 56.8% at 5 years. Of these 45 patients, 13 (28.9%) required medication to treat diabetes (DM) before SG and only five (11.1%) at 5 years after SG (61.5% decrease); 18 (40%) had antihypertensive treatment before SG, and eight (17.8%) at 5 years after SG (55.5% decrease); 12 (26.7%) took lipid-lowering medication before SG, and five (11.1%) at 5 years after SG (58.3% decrease); 24 (53.3%) had sleep apnea (SAS) before SG and six (17.8%) at 5 years after SG (75% decrease). However, while only five patients (11.1%) had GERD requiring PPI therapy before SG, 15 patients required PPI therapy (33.3%) at 5 years after SG (200% increase).

CONCLUSION

Five years after performance of SG, weight loss was satisfactory, few complications were observed, the reduction of co-morbidities was significant, but there was an increase in the frequency of GERD.

摘要

目的

评估袖状胃切除术(SG)术后 5 年的疗效和安全性。

患者和方法

2005 年 6 月至 2007 年 1 月,65 例肥胖患者接受了 SG。根据我们的数据库,在 SG 术后 2 年评估了超重减轻百分比(%EWL)和超重 BMI 减轻百分比(%EBL)、肥胖相关合并症和术后 SG 并发症,并根据其中一位作者(IB)于 2011 年 5 月至 2012 年 2 月之间通过问卷向患者发送的内容,在 SG 术后 5 年进行评估。

结果

53 例患者(82%)获得了完整的数据集,包括 45 例仅接受 SG 治疗的患者和 8 例因体重减轻不足而在以后进行了第二次减重手术的患者(5 例胃旁路术(GBP),3 例 SG 修正)。对于这 53 名患者,术后 2 年时的平均 EWL 为 54.4%,5 年时为 53.7%;术后 2 年时的平均 EBL 为 61%,5 年时为 60%。3 名患者(5.7%)出现术后并发症(2 例瘘管(3.8%),1 例出血(1.9%))。SG 术后 10 个月至 34 个月间观察到 3 例套管部位疝(5.7%)。仅接受 SG 治疗的 45 例患者的亚组分析显示,术后 2 年时的平均 EWL 为 57.1%,5 年时为 50.7%;术后 2 年时的平均 EBL 为 64%,5 年时为 56.8%。在这 45 名患者中,有 13 名(28.9%)在 SG 前需要药物治疗糖尿病(DM),而在 SG 后 5 年只有 5 名(11.1%)(61.5%减少);18 名(40%)在 SG 前有降压治疗,而在 SG 后 5 年只有 8 名(17.8%)(55.5%减少);12 名(26.7%)在 SG 前服用降脂药,而在 SG 后 5 年只有 5 名(11.1%)(58.3%减少);24 名(53.3%)有睡眠呼吸暂停(SAS),而在 SG 后 5 年只有 6 名(17.8%)(75%减少)。然而,尽管只有 5 名患者(11.1%)在 SG 前需要质子泵抑制剂(PPI)治疗 GERD,但在 SG 后 5 年,有 15 名患者需要 PPI 治疗(33.3%)(增加 200%)。

结论

SG 术后 5 年,体重减轻令人满意,并发症少,合并症减少显著,但 GERD 发病率增加。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验